Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 1, 2026

Conditions

Neoplasms

Interventions

BIOLOGICAL

Oncolytic Virus injection(IDOV-SAFETM)

Administered by intravenous injection as single agent.

Trial Locations (1)

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER